Eli Lilly- Incyte baricitinib meets primary end point in Phase IIb study
Baricitinib is an orally administered selective JAK1 and JAK2 inhibitor that is JAK3-sparing. A total of 301 patients, with active RA on stable doses of methotrexate, were randomized